Tag: 2018
Q1 Report 2018
ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update
Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109 in Endometriosis, results…
Q1 2018 ObsEva SA Earnings Conference Call
ObsEva Annual General Meeting 2018
Wednesday, May 9, 2018 Location: Geneva Supporting Materials:
ObsEva Annual General Meeting 2018
ObsEva SA to Hold First Quarter 2018 Financial Results and Business Update Call on May 16, 2018
Geneva, Switzerland and Boston, MA – May 8, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development…
ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) April 26, 2018 in New York City
ObsEva Announces Upcoming Presentations Related to its Endometriosis and Uterine Fibroid Development Programs with its Novel Oral GnRH Receptor Antagonist OBE2109 (KLH-2109)
ObsEva Announces Upcoming Presentations Related to its Endometriosis and Uterine Fibroid Development Programs with its Novel Oral GnRH Receptor Antagonist OBE2109 (KLH-2109)
(GLOBE NEWSWIRE via COMTEX) –ObsEva SA / ObsEva Announces Upcoming Presentations Related to its Endometriosis and Uterine Fibroid Development Programs…